Accessibility Menu
Cognition Therapeutics logo

Cognition Therapeutics

(NASDAQ) CGTX

Current Price$0.97
Market Cap$85.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-92%
5 YearN/A
1 Year+41%
1 Month-32%
Cognition Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.962026-07-17
Cognition Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.85%USD 1.092026-07-10
1 month-32.34%USD 1.422026-06-17
3 month-19.26%USD 1.192026-04-17
Year to date-28.83%USD 1.352025-12-31
1 year+41.29%USD 0.682025-07-17
3 year-45.72%USD 1.772023-07-18
Since inception-92.48%USD 12.772021-10-08

Cognition Therapeutics Financials at a Glance

Market Cap

$85.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.58M

EPS (TTM)

-$0.26

P/E Ratio

-3.73

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.97

Volume

468,028.093

Open

$0.94

Previous Close

$0.96

Daily Range

$0.92 - $0.98

52-Week Range

$0.55 - $3.83

Estimated Earnings Date

Aug 6, 2026

CGTX News

pile of pennies close up.jpg

Best Penny Stocks of 2026: Are They a Good Investment?

Keith NoonanMar 18, 2026
financial analysis company filing business papers

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

James BrumleySep 3, 2025
Foolcom-Featured.png

Cognition (CGTX) Q2 Grant Income Jumps

Motley Fool Markets TeamAug 8, 2025

CGTX: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cognition Therapeutics

Cognition Therapeutics develops medicines for brain and eye diseases. Its main drug aims to help people with memory loss. The company focuses on conditions like Alzheimer’s and vision problems in older adults.

Brainy Business: Products and Services

  • Zervimesine (CT1812): Oral drug in clinical trials for Alzheimer’s, dementia with Lewy bodies, and vision loss; 0% of revenue as of 2025.
  • CT2168: Early-stage drug for Parkinson’s and related brain disorders; 0% of revenue.
  • CT2074: Experimental treatment for age-related vision loss; 0% of revenue.
  • Small molecule research platform: Proprietary technology to discover new drugs for brain and eye diseases; 0% of revenue.
  • Grant-funded clinical programs: All income comes from research grants, not product sales; 100% of revenue in 2025.

Growth Spurts and Strategic Moves

  • Advanced zervimesine through multiple Phase 2 trials from 2023 to 2025.
  • Launched expanded access program for dementia with Lewy bodies in June 2025.
  • Partnered with Alzheimer’s Clinical Trial Consortium and received grants from the National Institute on Aging since 2021.
  • Concluded Phase 2 study in age-related vision loss in 2025 to focus on dementia programs.
  • Secured FDA Fast Track designation for zervimesine in Alzheimer’s disease in 2017.

What Makes Cognition Therapeutics Stand Out

The company uses a unique approach to target toxic proteins in the brain, different from standard antibody treatments. It relies on grant funding, reducing dependence on selling shares. Strategic partnerships with research groups and government agencies support its clinical trials.

Five Things You Need to Know

  • All 2025 revenue came from grants; no product sales reported.
  • Net loss was $23.5 million in 2025, improving 30.9% from 2024.
  • Operating expenses fell 11.4% to $47.8 million in 2025.
  • Cash and equivalents totaled $37.0 million at year-end 2025.
  • Company had 25 employees in 2025, down to 14 by March 2026.

Bottom Line

Cognition Therapeutics remains focused on developing new drugs for brain and eye diseases. Its progress depends on clinical trial results and continued grant funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14

CEO

Lisa R. Ricciardi, MBA

Website

www.cogrx.com

Headquarters

Purchase, NY 10577, US

CGTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-72.68%

Return on Capital

-136.92%

Return on Assets

-54.17%

Earnings Yield

-26.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$85.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

89.50M

Volume

468.03K

Avg. Volume

1.55M

Financials (TTM)

Gross Profit

-$129.00K

Operating Income

-$42.84M

EBITDA

-$19.31M

Operating Cash Flow

-$20.25M

Capital Expenditure

$0.00

Free Cash Flow

-$20.25M

Cash & ST Invst.

$31.13M

Total Debt

$465.00K

Cognition Therapeutics Performance Analysis

Cognition Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cognition Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cognition Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.741.0%
20232023-12-31USD -0.8616.4%
20242024-12-31USD -0.86-0.4%
20252025-12-31USD -0.32-62.2%
Cognition Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.4%
Q32025-09-3042.5%
Q42025-12-3140.5%
Q12026-03-31-36.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$68.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$85.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.14M

N/A

Employees

14

N/A

Net Income

-$4.57M

+46.1%

EBITDA

-$4.50M

+46.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$31.13M

+89.5%

Total Debt

$465.00K

-26.8%

Accounts Receivable

$3.66M

-23.5%

Inventory

$0.00

N/A

Long Term Debt

$176.00K

-37.1%

Short Term Debt

$289.00K

-18.6%

Return on Assets

-54.17%

N/A

Return on Invested Capital

-1.42%

N/A

Free Cash Flow

-$5.54M

+43.9%

Operating Cash Flow

-$5.54M

+43.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SPROSpero Therapeutics, Inc.
$1.58+0.64%
SEERSeer, Inc.
$2.17+0.46%
MCRBSeres Therapeutics, Inc.
$5.33+2.90%
ATOSAtossa Therapeutics, Inc.
$2.49+4.18%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
JOBYJoby Aviation
$7.23-0.01%

Questions About CGTX

What is the current price of Cognition Therapeutics?

Cognition Therapeutics is trading at $0.96 per share.

What is the 52-week range for Cognition Therapeutics?

Over the past 52 weeks, Cognition Therapeutics has traded between $0.55 and $3.83.

How much debt does Cognition Therapeutics have?

As of the most recent reporting period, Cognition Therapeutics reported total debt of $465.00K.

How much cash does Cognition Therapeutics have on hand?

Cognition Therapeutics reported $31.23M in cash and cash equivalents in its most recent financial results.

What is Cognition Therapeutics’s dividend yield?

Cognition Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services